465 related articles for article (PubMed ID: 29978248)
1. Therapeutic cancer vaccine: building the future from lessons of the past.
Tran T; Blanc C; Granier C; Saldmann A; Tanchot C; Tartour E
Semin Immunopathol; 2019 Jan; 41(1):69-85. PubMed ID: 29978248
[TBL] [Abstract][Full Text] [Related]
2. Targeting Resident Memory T Cells for Cancer Immunotherapy.
Blanc C; Hans S; Tran T; Granier C; Saldman A; Anson M; Oudard S; Tartour E
Front Immunol; 2018; 9():1722. PubMed ID: 30100906
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
4. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH
Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145
[TBL] [Abstract][Full Text] [Related]
5. Vaccines targeting helper T cells for cancer immunotherapy.
Melssen M; Slingluff CL
Curr Opin Immunol; 2017 Aug; 47():85-92. PubMed ID: 28755541
[TBL] [Abstract][Full Text] [Related]
6. [Anti-cancer vaccines: What future in anti-cancer immunotherapy strategies?].
Tartour E
Biol Aujourdhui; 2018; 212(3-4):69-76. PubMed ID: 30973134
[TBL] [Abstract][Full Text] [Related]
7. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
8. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy: moving forward with peptide T cell vaccines.
Kumai T; Fan A; Harabuchi Y; Celis E
Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
[TBL] [Abstract][Full Text] [Related]
10. CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells.
Trella E; Raafat N; Mengus C; Traunecker E; Governa V; Heidtmann S; Heberer M; Oertli D; Spagnoli GC; Zajac P
Eur J Immunol; 2016 Feb; 46(2):420-31. PubMed ID: 26561341
[TBL] [Abstract][Full Text] [Related]
11. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
12. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
13. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
Front Immunol; 2018; 9():2481. PubMed ID: 30455687
[TBL] [Abstract][Full Text] [Related]
15. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
Saxena M; Bhardwaj N
Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies utilizing neoepitope-targeted vaccines.
Lee KL; Schlom J; Hamilton DH
Cancer Immunol Immunother; 2021 Apr; 70(4):875-885. PubMed ID: 33033852
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
[TBL] [Abstract][Full Text] [Related]
19. Resident memory T cells, critical components in tumor immunology.
Mami-Chouaib F; Blanc C; Corgnac S; Hans S; Malenica I; Granier C; Tihy I; Tartour E
J Immunother Cancer; 2018 Sep; 6(1):87. PubMed ID: 30180905
[TBL] [Abstract][Full Text] [Related]
20. Increasing the efficacy of tumor cell vaccines by enhancing cross priming.
Andersen BM; Ohlfest JR
Cancer Lett; 2012 Dec; 325(2):155-64. PubMed ID: 22809568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
